busulfan + ciprofloxacin + cyclophosphamide + pentoxifylline

This is a combination drug regimen used primarily as a conditioning regimen prior to hematopoietic stem cell transplantation. The combination includes: - **Busulfan**: An alkylating agent used in conditioning regimens prior to allogeneic hematopoietic progenitor cell transplantation, particularly for chronic myelogenous leukemia. - **Ciprofloxacin**: A fluoroquinolone antibiotic included in the regimen, potentially to prevent infections during the transplantation process. - **Cyclophosphamide**: An alkylating agent commonly combined with busulfan in conditioning regimens for blood and marrow transplantation. - **Pentoxifylline**: A methylxanthine derivative that improves blood flow by increasing erythrocyte flexibility, reducing plasma fibrinogen, inhibiting neutrophil activation, and suppressing erythrocyte/platelet aggregation. It also has antioxidant and anti-inflammatory effects. This combination has been studied in the context of dose escalation for conditioning regimens in patients undergoing autologous or allogeneic hematopoietic stem cell transplantation.